Related references
Note: Only part of the references are listed.Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2021)
Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition
Shirin Bajaj et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
C. N. Owen et al.
ANNALS OF ONCOLOGY (2020)
Systemic Therapy for Melanoma: ASCO Guideline
Rahul Seth et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O. Michielin et al.
ANNALS OF ONCOLOGY (2020)
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Alexander M. M. Eggermont et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2020)
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Alexander M. M. Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2019)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E. Gershenwald et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines
Emanuela Romano et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)